Access Pharmaceuticals, Inc.
Dallas, TX United States
(OTC: ACCP)

Company Description

Access Pharmaceuticals is developing treatments to tap into the cancer therapy market. The company makes pharmaceutical products based on nanopolymer chemistry and other drug delivery technologies. Its FDA-approved MuGard is a prescription oral rinse for the treatment of mucositis, or mouth ulceration, a common side effect of chemotherapy or radiation. MuGard has marketing approval in the US, and it is available in Europe through partner SpePharm. MuGard is also awaiting regulatory approvals for certain markets in Asia. Other Access products, including ovarian cancer candidate ProLindac and treatments and drug delivery technologies for solid tumors and diabetes, are in clinical and preclinical development.

2600 N. Stemmons Fwy., Ste. 176	Phone: 214-905-5100	http://www.accesspharma.com
Dallas, TX 75207	Fax: 214-905-5101	Map This Company
United States

Try a Full Premium Subscription

Access over 85 million companies
Call (866) 443-3939 or

Access Pharmaceuticals, Inc. Rankings

Executives

15 executives listed for Access Pharmaceuticals, Inc.'s Dallas, TX location.
Chairman	Steven Rouhandeh	E-mail
Vice Chairman, Europe and Senior Director, Oncology Clinical Research and Development	Esteban Cvitkovic	E-mail
CEO and Director; President, SCO Financial Group LLC	Jeffrey Davis	E-mail

More Access Pharmaceuticals, Inc. Executives

Financials

Company Type	Public - OTC: ACCP Headquarters
Fiscal Year-End	December
2011 Employees	14

More Access Pharmaceuticals, Inc. Financials

Social Media Center

DNBi

Leverage D&B's credit assessment tools to positively impact
your business. Get the scoop on Access Pharmaceuticals, Inc. now.

Reduce risk.
Drive greater profitability.
Increase cash flow.

Access Pharmaceuticals, Inc.Dallas, TX United States (OTC: ACCP)